A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I Disorder

Abstract

Aripiprazole, 15 or 30 mg/day, was superior to placebo in maintaining efficacy in patients with bipolar I disorder with a recent manic or mixed episode who were stabilized and maintained on aripiprazole treatment for 6 weeks, as shown by a longer time to relapse.